BioHive Utah · Jun 2026
BioHive Utah highlighted Eris Biotech as the 2026 Women in Tech & Science Award winner and noted it was co-founded by Evita Weagel and Rachel Brog Garlick.
Our drugs engage the immune system to fight tumors
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Eris Biotech is a Utah-based biotechnology research startup developing oral small-molecule cancer therapeutics that block tumor immune evasion and aim to reawaken the immune system, starting with mesothelioma.
Primary product
Oral small-molecule immuno-oncology therapy platform / hypoxia-activated prodrugs for solid tumors
Founded
2023
Headquarters
Lehi, Utah, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Oncology / immuno-oncology
Offices
0 jobs at Eris Biotech
Check back later for new openings
Business model
Investors
Mission-driven, patient-centered biotech focused on safer cancer treatments with lower systemic toxicity; public benefits details were not found.
Differentiators
Technology
Competitors
Estimated revenue
Less than $1M
Estimated monthly visits
397
Traffic estimate as of Jun 2026
BioHive Utah · Jun 2026
BioHive Utah highlighted Eris Biotech as the 2026 Women in Tech & Science Award winner and noted it was co-founded by Evita Weagel and Rachel Brog Garlick.
Eris Biotech / LinkedIn · Oct 2025
Eris Biotech announced that CEO Evita Weagel was recognized with the Women’s Tech Award for biotech disruption.
Eris Biotech / LinkedIn · Aug 2025
The company announced selection into MSK’s 2025 Therapeutics Accelerator, highlighting collaboration with MSK scientists and commercialization experts on its oral small-molecule therapy.
BioUtah · Feb 2024
BioUtah announced Eris Biotech’s acceptance into Y Combinator and summarized the company’s hypoxia-activated prodrug approach for solid tumors and mesothelioma.
Y Combinator · Feb 2024
YC introduced Eris Biotech’s launch, explaining its hypoxia-activated prodrug approach, tumor-local drug activation, and mesothelioma lead program.